HSV-1 Us9-30 Mutant as a Candidate HSV Vaccine in a Mouse Ocular Model | IOVS

HSV-1 Us9-30 Mutant as a Candidate HSV Vaccine in a Mouse Ocular Model | IOVS

Lyon, France – Le 16 octobre 2014 – Sanofi Pasteur, la division vaccins de Sanofi et Immune Design Corp., société de stade clinique qui développe des produits d’immunothérapie, annoncent aujourd’hui le début d’une collaboration étendue pour le développement d’une thérapie immunitaire contre le virus Herpes simplex (HSV). We first replicated this study, and then two assessors reviewed the articles and extracted information on vaccine effectiveness, cost of HZ, other modelling assumptions and QALY estimates. New recommendation: HPV2 and HPV4 vaccines may be administered to non-immunocompromised, non-HIV infected, individuals 9-14 years of age as two separate 0.5 mL doses at months 0 and 6-12. Here, we showed that intranasal immunization with live HSV-2 TK(-) induced the production of effector T cells and their migration to, and retention in, the vaginal mucosa, whereas systemic vaccination barely established a local effector T cell pool, even when it induced the production of circulating memory T cells in the systemic compartment. HSV-2 gC2 and gE2 on the virus blocked neutralization by gD2 antibody, while HSV-1 gC1 and gE1 did not block neutralization by gD2 antibody. Available antiviral and analgesic treatments are relatively unsatisfactory in reducing pain and length of the disease. It is paradoxical that one of the best varicella vaccines (the Oka strain) has been developed in Japan and recommended by the World Health Organization (WHO), whereas it is not listed in the routine vaccination program in Japan with only a 20-30% coverage rate among children (4).
HSV-1 Us9-30 Mutant as a Candidate HSV Vaccine in a Mouse Ocular Model | IOVS

At forty days post-infection photographs were taken of the mice and the right and left corneas were removed and assayed using FACS analysis. Associé à un antigène et injecté à un patient, GLA est capté par les cellules dendritiques (DC) et induit la production et l’expansion de lymphocytes T auxiliaires CD4 possédant un phénotype Th1. Cost assumptions, discount rate assumptions, assumptions about vaccine efficacy and waning and epidemiological assumptions drove variation in the outcomes. Corneas infected with Us9-30 mutant had a modest increase in Cd45+ cells compared with corneas treated with saline alone. We found that these vaginal effector memory T cells are critical for the early stage of viral clearance at natural infection sites and prevent severe vaginal inflammation and herpes encephalitis. Sixty percent of genital disease in control subjects was caused by HSV-1, which has emerged as the leading cause of primary genital disease [1, 3]. Conclusions: Ocular infection with Us9-30 mutant reduces the clinical response of subsequent wild-type HSV infection.

So it is warranted to conduct further analyses based on the Kaiser Permanente of Northern California Health Care Delivery System.

You may also like